Skip to main content

Advertisement

Log in

Diet, weight loss, and cardiovascular disease prevention

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Body weight, like cholesterol and blood pressure, are continuous variables. Overweight results when energy intake as food exceeds energy expenditure from exercise for a considerable period of time. When body weight becomes sufficiently high, it poses a risk to cardiovascular and metabolic health. The types of treatments considered by the physician and discussed with a patient should be based on this risk-benefit assessment. The body mass is the basic measurement for this assessment, and should be part of the “vital signs” when a patient is first evaluated by the medical staff. When the body mass index (BMI) is below 25 kg/m2, there is little risk from the body weight, but because obesity is a “stigmatized” condition, many patients, particularly women, desire to lose weight even within the normal range. For this purpose, a high-quality diet like the Dietary Approaches to Stopping Hypertension (DASH) diet at a reduced-calorie intake would be our recommendation. When the BMI is above 25 kg/m2, patients deserve dietary advice, but in addition to a reduced-calorie DASH-like diet, this is a place to consider using “portion-control” strategies, such as the nutrition labels that manufacturers provide on canned and frozen foods to guide patients in reducing calorie intake. In overweight individuals at high risk (ie, those with a BMI above 30 kg/m2 or impaired glucose tolerance, hypertension, or the metabolic syndrome), the use of orlistat or sibutramine along with diet, exercise, lifestyle changes, and portion control should be considered. When the BMI is above 35 kg/m2, bariatric surgery should also be discussed as an option for the "at-risk" individual. Evidence reviewed here shows that modest weight losses of 5% to 10% can reduce the risk of conversion from impaired glucose tolerance to diabetes and can maintain lower blood pressure over extended periods. All of the approaches described above can produce weight losses of this magnitude.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Flegal KM, Carroll MD, Ogden CL, et al.: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727. Documents the increasing prevalence of overweight and obesity. In this most recent survey, 64.5% of adults over 20 are overweight, and 30.5% are obese, with important differences in ethnic and gender distribution of this obesity.

    Article  PubMed  Google Scholar 

  2. Kuczmarski RJ, Flegal KM, Campbell SM, et al.: Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994, 272:205–211.

    Article  PubMed  CAS  Google Scholar 

  3. Stevens VJ, Obarzanek E, Cook NR, et al.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134:1–11.

    PubMed  CAS  Google Scholar 

  4. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin [no authors listed]. N Engl J Med 2002, 346:393–403. Reports the experience with lifestyle intervention and metformin in reducing the rate of conversion from IGT to diabetes over a 2.8-year follow-up. The rate of conversion was reduced by 58% among individuals treated with lifestyle intervention, who lost an average of 7 kg, and reduction of 31% among the subjects treated with metformin.

  5. National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497. Describes a proposal for diagnostic criteria for the metabolic syndrome, as well as laying out a therapeutic strategy for treatment of individuals at high, moderate, and low risk for cardiovascular disease. They also indicate that diabetes is now a "coronary" risk equivalent, because of the added risk for developing cardiovascular disease among diabetic patients.

  6. Bray GA, Greenway FL: Current and potential drugs for treatment of obesity. Endocr Rev 1999, 20:805–875.

    Article  PubMed  CAS  Google Scholar 

  7. Sjostrom L, Rissanen A, Andersen T, et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167–172.

    Article  PubMed  CAS  Google Scholar 

  8. Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242.

    Article  PubMed  CAS  Google Scholar 

  9. Rossner S, Sjostrom L, Noack R, et al.: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000, 8:49–61.

    Article  PubMed  CAS  Google Scholar 

  10. Hauptman J, Lucas C, Boldrin MN, et al.: Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000, 9:160–167.

    Article  PubMed  CAS  Google Scholar 

  11. Sjostrom L: The XENDOS Study. Paper presented at 9th International Congress on Obesity. Sao Paulo, Brazil; August 24–29, 2002.

  12. Hollander PA, Elbein SC, Hirsch IB, et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288–1294.

    Article  PubMed  CAS  Google Scholar 

  13. Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321–1326.

    Article  PubMed  CAS  Google Scholar 

  14. Reaven G, Segal K, Hauptman J, et al.: Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001, 87:827–831.

    Article  PubMed  CAS  Google Scholar 

  15. Mittendorfer B, Ostlund R, Patterson BW, et al.: Orlistat inhibits dietary cholesterol absorption. Obes Res 2001, 9:599–604.

    PubMed  CAS  Google Scholar 

  16. Bray GA, Blackburn GL, Ferguson JM, et al.: Sibutramine: a dose-ranging and long-term efficacy study in the treatment of obesity. Obes Res 1999, 7:189–198.

    PubMed  CAS  Google Scholar 

  17. James WP, Astrup A, Finer N, et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356:2119–2125.

    Article  PubMed  CAS  Google Scholar 

  18. Wirth A, Krause J: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001, 286:1331–1339.

    Article  PubMed  CAS  Google Scholar 

  19. McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000, 160:2185–2191.

    Article  PubMed  CAS  Google Scholar 

  20. McMahon FG, Weinstein SP, Rowe E, et al.: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002, 16:5–11.

    Article  PubMed  CAS  Google Scholar 

  21. Fujioka K, Seaton TB, Rowe E, et al.: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diab Obes Metab 2000, 2:1–13.

    Article  Google Scholar 

  22. Wadden TA, Berkowitz RI, Sarwer DB, et al.: Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001, 161:218–227.

    Article  PubMed  CAS  Google Scholar 

  23. Wadden TA, Berkowitz RI, Womble LG, et al.: Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000, 8:431–437.

    PubMed  CAS  Google Scholar 

  24. Sjostrom CD, Lissner L, Wedel H, et al.: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999, 7:477–484.

    PubMed  CAS  Google Scholar 

  25. Sjostrom CD, Peltonen M, Wedel H, et al.: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000, 36:20–25.

    PubMed  CAS  Google Scholar 

  26. Heymsfield SB, Allison DB, Vasselli JR, et al.: Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998, 280:1596–1600.

    Article  PubMed  CAS  Google Scholar 

  27. Pittler MH, Abbot NC, Harkness EF, et al.: Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999, 53:379–381.

    Article  PubMed  CAS  Google Scholar 

  28. Boozer CN, Nasser JA, Heymsfield SB, et al.: An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001, 25:316–324.

    Article  PubMed  CAS  Google Scholar 

  29. Boozer CN, Daly PA, Homel P, et al.: Herbal ephedra/ caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002, 26:593–604.

    Article  PubMed  CAS  Google Scholar 

  30. Verdich C, Flint A, Gutzwiller JP, et al.: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001, 86:4382–4389.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bray, G.A., Ryan, D.H. & Harsha, D.W. Diet, weight loss, and cardiovascular disease prevention. Curr Treat Options Cardio Med 5, 259–269 (2003). https://doi.org/10.1007/s11936-003-0025-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-003-0025-9

Keywords

Navigation